Healthy Volunteers Clinical Trial
Official title:
A Phase I, Randomized, Dose-Ranging, Pharmacokinetic, Glucodynamic, Safety, and Tolerability Study of SC Administered Humulin R and Humalog With or Without Recombinant Human Hyaluronidase (rHuPH20) in Healthy Volunteers
This is a single center, Phase I, open-label, single-blind (subjects blinded to the contents of each injection), 4 stage study designed to determine the PK, GD, safety, tolerability, and optimal ratio of rHuPH20 administered with fixed Humulin R or Humalog doses in healthy subjects.
Subjects will be enrolled in one of four sequential study stages. In each stage, a euglycemic
clamp procedure will be used to control plasma glucose levels. Blood samples will be
collected over an 8-hour time period after insulin administration (either Humulin R or
Humalog) to analyze insulin and glucose levels using fully validated methods. Glucose
infusion rates (GIR) will be recorded throughout the study period. The study is single-blind,
with study subjects blinded as to the contents of each injection.
Determine the pharmacokinetics (PK) and optimum ratio of rHuPH20:insulin when a range of
rHuPH20 dose ratios are administered subcutaneously (SC) with fixed doses of Humulin R, by
determining Tmax, Cmax, AUCs, and relative bioavailability based on serum insulin
concentrations collected at specified time points (Stage 1).
Determine if different concentrations of Humulin R impact the PK and minimal rHuPH20 dose
necessary to achieve full insulin PK effect over a representative range of typical prandial
SC Humulin R doses using the rHuPH20:insulin ratio identified in Stage 1 (Stage 2).
Determine the PK and optimum ratio of rHuPH20:insulin when a range of rHuPH20 dose ratios are
administered SC with fixed doses of Humalog, by determining Tmax, Cmax, AUCs, and relative
bioavailability based on serum insulin concentrations collected at specified time points
(Stage 3).
Determine if different concentrations of Humalog impact the PK and minimal rHuPH20 dose
necessary to achieve full insulin PK effect over a representative range of typical prandial
SC Humalog doses using the rHuPH20:insulin ratio identified in Stage 3 (Stage 4).
Evaluate the safety and local tolerability of the SC injection at various rHuPH20, Humulin R,
and Humalog doses (Stages 1 - 4).
Assess the glucodynamics (GD) of the SC injection of various rHuPH20, Humulin R, and Humalog
doses (Stages 1 - 4).
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05001152 -
Taste Assessment of Ozanimod
|
Phase 1 | |
| Completed |
NCT05029518 -
3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability
|
Phase 1 | |
| Completed |
NCT04493255 -
A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants
|
Phase 1 | |
| Completed |
NCT03457649 -
IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT00995891 -
Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
|
||
| Completed |
NCT05050318 -
Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively
|
Phase 4 | |
| Completed |
NCT05043766 -
Evaluation of Oral PF614 Relative to OxyContin
|
Phase 1 | |
| Completed |
NCT04466748 -
A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects
|
Phase 1 | |
| Completed |
NCT00746733 -
Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC
|
Phase 1 | |
| Recruiting |
NCT05929651 -
Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy
|
Phase 4 | |
| Completed |
NCT05954039 -
Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect
|
N/A | |
| Completed |
NCT05045716 -
A Study of Subcutaneous Lecanemab in Healthy Participants
|
Phase 1 | |
| Active, not recruiting |
NCT02747927 -
Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children
|
Phase 3 | |
| Completed |
NCT05533801 -
A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants
|
Phase 1 | |
| Not yet recruiting |
NCT03931369 -
Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST)
|
Phase 2 | |
| Completed |
NCT03279146 -
A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT06027437 -
A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants
|
Phase 1 | |
| Recruiting |
NCT05619874 -
Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity
|
N/A | |
| Completed |
NCT05553418 -
Investigational On-body Injector Clinical Study
|
N/A | |
| Completed |
NCT04092712 -
Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers
|
Phase 1 |